다우존스 지수

실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.

등록

OGEN

Oragenics (OGEN)

Oragenics Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:AMEX:OGEN

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/23	22:27	Edgar (US Regulatory)	Form 8-K - Current report	AMEX:OGEN	Oragenics Inc
2024/05/22	21:00	Edgar (US Regulatory)	Form 8-K - Current report	AMEX:OGEN	Oragenics Inc
2024/05/22	21:00	GlobeNewswire Inc.	Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer	AMEX:OGEN	Oragenics Inc
2024/05/17	21:00	Edgar (US Regulatory)	Form 8-K - Current report	AMEX:OGEN	Oragenics Inc
2024/05/17	21:00	GlobeNewswire Inc.	Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine	AMEX:OGEN	Oragenics Inc
2024/05/16	21:00	Edgar (US Regulatory)	Form 8-K - Current report	AMEX:OGEN	Oragenics Inc
2024/05/16	21:00	GlobeNewswire Inc.	Oragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion Trial	AMEX:OGEN	Oragenics Inc
2024/05/16	02:00	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	AMEX:OGEN	Oragenics Inc
2024/05/07	21:14	Edgar (US Regulatory)	Form 8-K - Current report	AMEX:OGEN	Oragenics Inc
2024/05/07	21:00	GlobeNewswire Inc.	Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia	AMEX:OGEN	Oragenics Inc
2024/04/20	06:50	Business Wire	Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards	AMEX:OGEN	Oragenics Inc
2024/04/01	22:05	Business Wire	Oragenics, Inc. Files 10K and Provides Company Update	AMEX:OGEN	Oragenics Inc
2024/03/18	20:00	Business Wire	Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion	AMEX:OGEN	Oragenics Inc
2024/03/07	06:24	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	AMEX:OGEN	Oragenics Inc
2024/03/05	21:45	Business Wire	Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion	AMEX:OGEN	Oragenics Inc
2024/03/02	06:04	Business Wire	Oragenics Announces Closing of Public Offering	AMEX:OGEN	Oragenics Inc
2024/03/01	06:41	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	AMEX:OGEN	Oragenics Inc
2024/02/28	23:03	Edgar (US Regulatory)	Form 8-K - Current report	AMEX:OGEN	Oragenics Inc
2024/02/28	11:25	Business Wire	Oragenics Announces Pricing of Public Offering	AMEX:OGEN	Oragenics Inc
2024/02/28	07:09	Edgar (US Regulatory)	Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses	AMEX:OGEN	Oragenics Inc
2024/02/28	07:04	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	AMEX:OGEN	Oragenics Inc
2024/02/28	06:33	Business Wire	Oragenics Announces Proposed Public Offering	AMEX:OGEN	Oragenics Inc
2024/02/13	10:06	Edgar (US Regulatory)	Form SC 13D - General statement of acquisition of beneficial ownership	AMEX:OGEN	Oragenics Inc
2024/02/13	06:45	Edgar (US Regulatory)	Form 8-K - Current report	AMEX:OGEN	Oragenics Inc
2024/02/13	06:41	Business Wire	Oragenics, Inc. Announces Leadership Transition	AMEX:OGEN	Oragenics Inc
2024/02/07	22:00	Edgar (US Regulatory)	Form 8-K - Current report	AMEX:OGEN	Oragenics Inc
2024/02/07	22:00	Business Wire	Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement	AMEX:OGEN	Oragenics Inc
2024/02/05	22:00	Edgar (US Regulatory)	Form 8-K - Current report	AMEX:OGEN	Oragenics Inc
2024/02/05	22:00	Business Wire	Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion	AMEX:OGEN	Oragenics Inc
2024/01/24	07:34	Business Wire	Oragenics Announces Termination of At-The-Market Offering Program	AMEX:OGEN	Oragenics Inc

검색 관련기사 보기:AMEX:OGEN

1 2 3 4 5 6 7 8 9 10 다음 >>

Vontobel Financial Produ...

Northern Empire Bancshares

High Dividend Equity Por...

Mobile Star (CE)

VALOUR ETH0E INAV

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관